Hims & Hers Health (NYSE:HIMS) Stock Price Down 3.8% – What’s Next?

Hims & Hers Health, Inc. (NYSE:HIMS)’s stock price was down 3.8% on Monday . The company traded as low as $43.81 and last traded at $47.40. Approximately 17,903,515 shares were traded during trading, an increase of 0% from the average daily volume of 17,886,535 shares. The stock had previously closed at $49.28.

Analyst Upgrades and Downgrades

HIMS has been the topic of a number of research analyst reports. Bank of America upped their price target on Hims & Hers Health from $18.00 to $21.00 and gave the stock an “underperform” rating in a research note on Thursday. Piper Sandler increased their price target on shares of Hims & Hers Health from $21.00 to $24.00 and gave the stock a “neutral” rating in a research report on Monday, January 6th. Morgan Stanley cut shares of Hims & Hers Health from an “overweight” rating to an “equal weight” rating and raised their price target for the company from $42.00 to $60.00 in a research report on Tuesday, February 18th. BTIG Research started coverage on Hims & Hers Health in a report on Tuesday, January 7th. They issued a “buy” rating and a $35.00 target price for the company. Finally, Needham & Company LLC upped their price target on Hims & Hers Health from $28.00 to $31.00 and gave the stock a “buy” rating in a report on Monday, January 6th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have issued a buy rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average target price of $28.53.

Hims & Hers Health Price Performance

The company has a 50-day simple moving average of $35.05 and a 200-day simple moving average of $25.83. The stock has a market cap of $11.03 billion, a PE ratio of 114.94 and a beta of 1.35.

Insider Activity

In other Hims & Hers Health news, CFO Oluyemi Okupe sold 18,959 shares of the business’s stock in a transaction on Friday, December 20th. The stock was sold at an average price of $25.77, for a total transaction of $488,573.43. Following the sale, the chief financial officer now directly owns 132,578 shares in the company, valued at approximately $3,416,535.06. The trade was a 12.51 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, insider Soleil Boughton sold 2,343 shares of the firm’s stock in a transaction on Tuesday, November 26th. The shares were sold at an average price of $29.90, for a total value of $70,055.70. Following the completion of the transaction, the insider now owns 165,254 shares of the company’s stock, valued at approximately $4,941,094.60. This represents a 1.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 1,082,618 shares of company stock worth $37,317,410 in the last 90 days. 17.71% of the stock is currently owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

Institutional investors and hedge funds have recently made changes to their positions in the business. SlateStone Wealth LLC raised its position in Hims & Hers Health by 4.0% during the fourth quarter. SlateStone Wealth LLC now owns 10,640 shares of the company’s stock worth $257,000 after acquiring an additional 413 shares during the last quarter. Blume Capital Management Inc. raised its position in shares of Hims & Hers Health by 100.0% during the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after purchasing an additional 600 shares during the last quarter. Summit Investment Advisors Inc. lifted its stake in Hims & Hers Health by 3.3% in the 4th quarter. Summit Investment Advisors Inc. now owns 19,853 shares of the company’s stock valued at $480,000 after buying an additional 628 shares in the last quarter. Quest Partners LLC grew its holdings in Hims & Hers Health by 22.6% during the 3rd quarter. Quest Partners LLC now owns 4,373 shares of the company’s stock valued at $81,000 after buying an additional 807 shares during the last quarter. Finally, Harbour Investments Inc. grew its holdings in Hims & Hers Health by 18.8% during the 4th quarter. Harbour Investments Inc. now owns 5,269 shares of the company’s stock valued at $127,000 after buying an additional 833 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.